# A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcin

Source: https://onco.cc/trials/nct06976190/  
OnCo record `nct06976190` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of MRG003, Pucotenlimab, Gemcitabine in nasopharyngeal carcinoma, run by Lepu Biopharma Co., Ltd., now recruiting.

## Summary

A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma is a phase 3 interventional study registered as NCT06976190 by Lepu Biopharma Co., Ltd., with 446 participants planned, started 2025-05-06 and due to reach its primary completion in 2029-05. Interventions recorded: MRG003 + Pucotenlimab, Gemcitabine, Docetaxel, or Capecitabine. Conditions listed: Recurrent or Metastatic Nasopharyngeal Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06976190
- Phase: 3
- Setting: A Randomized, Open-label, Multi-center, Phase III Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
- Sponsor: Lepu Biopharma Co., Ltd.
- Enrolled: 446

## Sources

- ClinicalTrials.gov NCT06976190: https://clinicaltrials.gov/study/NCT06976190

## Connected records

- cancers: [Nasopharyngeal carcinoma](https://onco.cc/cancers/nasopharyngeal/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [MRG003](https://onco.cc/drugs/mrg003/), [Pucotenlimab](https://onco.cc/drugs/pucotenlimab/)
- companies: [Lepu Biopharma](https://onco.cc/companies/lepu-biopharma/)

---
JSON: https://onco.cc/api/v1/entities/nct06976190.json